Ad-hoc | 21 July 2004 13:28

STRATEC AG: EPS more than doubled

Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– EPS more than doubled Birkenfeld, July 21, 2004 The Board of Management of STRATEC Biomedical Systems AG, listed in the German Prime Standard and in Gate-M, hereby issues a precautionary announcement of the results for the first half year of 2004, ending on June 30, 2004, pursuant to Section 15 of the German Securities Trading Law (WpHG). STRATEC increased its earnings to EUR 1.229m (2003: EUR 0.526m). This results in undiluted earnings per share (EPS) amounting to EUR 0.37 (2003: EUR 0.16). These calculation is based on around 3.3 million shares. Sales was could be increased by 31.3% to EUR 18.304m (2003: EUR 13.939m). The overall performance improved by 29.6% to EUR 19.285m (2003: EUR 14.876m). At the end of the second quarter, STRATEC had 167 employees (2003: 142). Overview of Key Figures pursuant to IFRS (International Financial Reporting Standards): Key figures in 000s 01.01.-06.30.2004 01.01.-06.30.2003 Change Sales 18,304 13,939 +31.3% Overall performance 19,285 14,876 +29.6% EBITDA 2,519 1,400 +79.9% EBIT 2,076 964 +115.4% EBT 1,953 863 +126.3% Net income for the period 1,229 526 +133.7% end of ad-hoc-announcement (c)DGAP 21.07.2004 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: By means of logistical measures undertaken in the procurement and production divisions, it has largely been possible to neutralize the effects of the cycles traditionally observed within the course of business of a given financial year. The more extensive interim report can be downloaded from our homepage from around 3 p.m. on August 11, 2004. About STRATEC Biomedical Systems AG STRATEC (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems together with their own reagents to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the trading segment Gate-M of the Stuttgart Stock Exchange and on other exchanges. Further information can be obtained from: STRATEC Biomedical Systems AG Investor Relations André Loy Gewerbestraße 37 D-75217 Birkenfeld Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 eMail: ir@stratec-biomedical.de ——————————————————————————– WKN: 728900; ISIN: DE0007289001; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard) und Stuttgart; Freiverkehr in Berlin-Bremen, Düsseldorf und München 211328 Jul 04